 Features |
Welcome to
OsseoTECH, a site devoted to chronicling osseointegration developments Please send suggestions for features.
|
| Sponsors |
|
| Links |
CDE-Directory - A Comprehensive Guide to Continuing Dental Education
OsseoNews - The World of Implant Dentistry Online
PalmDMD - PDA's in clinical dentistry
Medgadget - Emerging Medical Technologies
PalmDDS - PDA's in clinical dentistry
CurrentJournals - Keeping you updated Automatically - Keywords, Journals, Authors delivered weekly in an easy to read PDF format
|
|
FDA Approval: Recombinant human bone morphogenetic protein-2 (rhBMP-2) |
Posted by:Editor
on Friday January 19th, 2007
|
Medtronic recently announced that the FDA Dental Products Advisory Panel has unanimously voted to recommend approval, with a condition the use of INFUSE® Bone Graft for certain oral and maxillofacial bone grafting procedures. INFUSE Bone Graft is recombinant human bone morphogenetic protein-2 (rhBMP-2) applied to an absorbable collagen sponge carrier. The purpose of the protein, which occurs naturally in the body, is to stimulate bone formation. It has been previously approved by the FDA for use in certain lumbar spine fusion and tibial fracture repair procedures. Implanted into a bone-deficient site, INFUSE Bone Graft works with the body’s own biology to induce normal physiologic bone formation.
More
<<< Back  E-Mail This Topic: Biologics
|
|
 |
! There are no comments posted for this item yet.
| |
